Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

BACKGROUND: Bortezomib, an NFkB inhibitor, is an active agent for the treatment of myeloma (MM). We have reported a promising complete remission (CR) rate for newly diagnosed myeloma patients treated by a staged approach, in which chemosensitive patients underwent autologous haematopoietic stem cell...

Descripción completa

Detalles Bibliográficos
Autor principal: Chim, Chor Sang
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003638/
https://www.ncbi.nlm.nih.gov/pubmed/21108845
http://dx.doi.org/10.1186/1479-5876-8-124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003638/
https://www.ncbi.nlm.nih.gov/pubmed/21108845
http://dx.doi.org/10.1186/1479-5876-8-124

Ejemplares similares